Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

Centrul de Oncologie Sf. Nectarie, Craiova, Romania

2 abstracts

Abstract
Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Expanded efficacy analysis from CheckMate 8HW.
Org: Bristol Myers Squibb, Cancer Research SA, Fondazione Policlinico Universitario A. Gemelli IRCCS, Institut Paoli-Calmettes, Marseille, France, Instituto Catalán de Oncología,
Abstract
Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW.
Org: University Medical Center Mainz, University Grenoble Alpes, CHU Grenoble Alpes, Institute for Advanced Biosciences, Kindai University Faculty of Medicine, Osaka-Sayama, Japan,